**Abstract**

**Objective:** Impaired glucose and energy metabolism may play a role in the pathobiology of schizophrenia. Abnormal brain energy metabolism has been found in animal models of schizophrenia. High fat, very low carbohydrate ketogenic diet (KD) induces adaptive changes in brain energy metabolism through bypassing impaired metabolic pathways and increasing energy reserves. We hypothesised that KD may have beneficial effects in schizophrenia. To test this hypothesis we studied the effects of KD in NMDA receptor hypofunction models of schizophrenia by measuring a variety of behavioural abnormalities reflecting positive, negative and cognitive aspects of schizophrenia.

**METHODS:** Acute NMDA receptor hypofunction was induced by a single injection of different doses of the non-competitive NMDA receptor antagonist dizocilpine (MK-801). For the chronic NMDA hypofunction model MK-801 (1 mg/kg) was administered daily for 4 weeks. Mice were fed with either standard mouse diet or KD (77.6, 9.5, 9.4 % and 30.8 MJ/kg fat, protein and carbohydrate content and digestible energy, respectively) for 3 and 7 weeks. Schizophrenia-like behaviours such as psychomotor hyperactivity, increased stereotyped behaviour, impaired sensorimotor gating; social interaction deficits and impaired working memory were measured following acute or chronic MK-801 administration.

**RESULTS:** KD effectively normalised the entire spectrum of schizophrenia-like behaviours, including psychomotor hyperactivity, stereotyped behaviour, impaired social interaction, spatial working memory deficits and impaired PPI induced by acute MK-801 administration. KD also normalised social interaction deficits induced by chronic (4 weeks) MK-801 administration. Furthermore, KD resulted in decreased body weight gain and lowering of blood glucose levels. Our analysis also confirmed that the beneficial behavioural effects of KD are independent of temporarily decreased calorie intake or body weight loss.

**CONCLUSIONS:** These results raise the possibility that KD might be effectively used to normalise schizophrenia-related behaviours. The beneficial metabolic effects suggest that KD may also help to mitigate metabolic abnormalities during antipsychotic treatment.
